Logo

AstraZeneca Presents Results of Imfinzi (durvalumab) + Tremelimumab in P-III POSEIDON Study as 1L Treatment for Stage IV NSCLC at WCLC 2021

Share this

AstraZeneca Presents Results of Imfinzi (durvalumab) + Tremelimumab in P-III POSEIDON Study as 1L Treatment for Stage IV NSCLC at WCLC 2021

Shots:

  • The P-III POSEIDON trial evaluates Imfinzi (1500mg- q3w- FD- for 4 cycles) + Pt-based CT or Imfinzi + Tremelimumab + CT vs CT alone in 1013 patients with mNSCLC
  • The results showed an improvement in OS & PFS- 28% reduction in risk of cancer progressing or death with an m-PFS (6.2 vs 4.8mos.)- 23% reduction in risk of death @16wks.- m-OS (14.0 vs 11.7mos.)- patients were alive @2yrs. (33% vs 22%). The safety profile was consistent with known profiles of therapies & no new safety signals were observed
  • Imfinzi is further being evaluated across all stages of lung cancer and in other tumor types. The combination therapy also tested for lung cancer- bladder cancer- and liver cancer

  | Ref: AstraZeneca | Image: New Europe

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions